重大事件
外國發行人報告
6-K
2026-07-13
諾和諾德更新股份回購進展 累計回購近2400萬股B股 總值約65億丹麥克朗
AI 繁中摘要
📊 諾和諾德（Novo Nordisk）提交6-K表格，更新股份回購計劃進展。
根據2026年5月6日啟動的回購計劃（屬總值150億丹麥克朗、為期12個月整體計劃一部分），公司於2026年7月6日至10日期間，每日回購195,000股B股，每股平均價格約320.62至327.75丹麥克朗，每日交易額約6,250萬至6,390萬丹麥克朗。累計自該次公佈以來，共回購9,225,000股B股，總值約27.345億丹麥克朗。
截至2026年7月10日，自2026年2月4日整體計劃啟動以來，諾和諾德已合共回購23,984,179股B股，平均每股272.45丹麥克朗，交易總值65.345億丹麥克朗。公司現持有41,169,480股庫存B股（每股面值0.10丹麥克朗），佔總股本約0.9%。
回購計劃將持續至2027年2月1日，剩餘回購額度約112億丹麥克朗。此舉反映管理層對公司價值的信心，並透過減少流通股份潛在提升每股盈利，對投資者屬正面信號。💰
諾和諾德為全球領先醫藥企業，專注糖尿病及嚴重慢性疾病，總部位於丹麥，B股在納斯達克哥本哈根上市，ADR在紐約證交所上市（代碼NVO）。
展開英文正文
6-K 1 f6k_071326.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 6-K ________________ REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 July 13, 2026 ________________ NOVO NORDISK A/S (Exact name of Registrant as specified in its charter) Novo Allé 1 DK- 2880, Bagsvaerd Denmark (Address of principal executive offices) ________________ Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F ☒ Form 40-F ☐ Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 13 July 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027. Since the announcement 6 July 2026, the following transactions have been made: Number of B shares Average purchase price Transaction value, DKK Accumulated, last announcement 8,250,000 2,419,775,981 6 July 2026 195,000 323.77 63,135,020 7 July 2026 195,000 327.75 63,910,282 8 July 2026 195,000 320.62 62,521,793 9 July 2026 195,000 320.72 62,540,384 10 July 2026 195,000 321.34 62,662,008 Accumulated under the programme 9,225,000 2,734,545,468 The details for each transaction made under the share repurchase programme are published on novonordisk.com. With the transactions stated above, Novo Nordisk owns a total of 41,169,480 B shares of DKK 0.10 as treasury shares, corresponding to 0.9% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares. Page 2 of 2 Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 10 July 2026, Novo Nordisk has since 4 February 2026 repurchased a total 23,984,179 B shares at an average share price of DKK 272.45 per B share equal to a transaction value of DKK 6,534,545,458. Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown Liz Skrbkova (US) +45 3079 9289 +1 609 917 0632 [email protected] [email protected] Investors: Michael Novod Jacob Martin Wiborg Rode +45 3075 6050 +45 3075 5956 [email protected] [email protected] Ida Schaap Melvold Sina Meyer +45 3077 5649 +45 3079 6656 [email protected] [email protected] Alex Bruce Christoffer Sho Togo Tullin +45 3444 2613 +45 3079 1471 [email protected] [email protected] Frederik Taylor Pitter Mads Berner Bruun +1 609 613 0568 +45 3075 2936 [email protected] [email protected] Novo Nordisk A/S Investor Relations Novo Allé 1 2880 Bagsværd Denmark Telephone: +45 4444 8888 www.novonordisk.com CVR no: 24 25 67 90 Company announcement No 42/ 2026 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized. Date: July 13, 2026 NOVO NORDISK A/S Maziar Mike Doustdar Chief Executive Officer